290 related articles for article (PubMed ID: 17671193)
1. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
Jin K; Park S; Ewton DZ; Friedman E
Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
[TBL] [Abstract][Full Text] [Related]
2. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
[TBL] [Abstract][Full Text] [Related]
3. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
4. The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling.
Jin K; Lim S; Mercer SE; Friedman E
J Biol Chem; 2005 Dec; 280(51):42097-105. PubMed ID: 16257974
[TBL] [Abstract][Full Text] [Related]
5. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells.
Lee K; Deng X; Friedman E
Cancer Res; 2000 Jul; 60(13):3631-7. PubMed ID: 10910078
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.
Dreissigacker U; Mueller MS; Unger M; Siegert P; Genze F; Gierschik P; Giehl K
Cell Signal; 2006 Aug; 18(8):1156-68. PubMed ID: 16257181
[TBL] [Abstract][Full Text] [Related]
7. Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas.
Mercer SE; Ewton DZ; Shah S; Naqvi A; Friedman E
Cancer Res; 2006 May; 66(10):5143-50. PubMed ID: 16707437
[TBL] [Abstract][Full Text] [Related]
8. Activation of Raf-1 in human pancreatic adenocarcinoma.
Berger DH; Jardines LA; Chang H; Ruggeri B
J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
[TBL] [Abstract][Full Text] [Related]
9. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
[TBL] [Abstract][Full Text] [Related]
11. Early requirement of Rac1 in a mouse model of pancreatic cancer.
Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
[TBL] [Abstract][Full Text] [Related]
12. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells.
Hirano T; Shino Y; Saito T; Komoda F; Okutomi Y; Takeda A; Ishihara T; Yamaguchi T; Saisho H; Shirasawa H
Oncogene; 2002 Aug; 21(38):5923-8. PubMed ID: 12185592
[TBL] [Abstract][Full Text] [Related]
13. Molecular target-based therapy of pancreatic cancer.
Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
[TBL] [Abstract][Full Text] [Related]
14. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
Sawai H; Okada Y; Kazanjian K; Kim J; Hasan S; Hines OJ; Reber HA; Hoon DS; Eibl G
Cancer Res; 2005 Dec; 65(24):11536-44. PubMed ID: 16357163
[TBL] [Abstract][Full Text] [Related]
15. Survival regulation in pancreatic cancer cells by c-Jun.
Okutomi Y; Shino Y; Komoda F; Hirano T; Ishihara T; Yamaguchi T; Saisho H; Shirasawa H
Int J Oncol; 2003 Oct; 23(4):1127-34. PubMed ID: 12963995
[TBL] [Abstract][Full Text] [Related]
16. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
18. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
[TBL] [Abstract][Full Text] [Related]
19. Dominant-negative Rac1 suppresses Ras-induced apoptosis possibly through activation of NFkappaB in Ha-ras oncogene-transformed NIH/3T3 cells.
Chou CK; Liang KH; Tzeng CC; Huang GC; Chuang JI; Chang TY; Liu HS
Life Sci; 2006 Mar; 78(16):1823-9. PubMed ID: 16274703
[TBL] [Abstract][Full Text] [Related]
20. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.
Baines AT; Lim KH; Shields JM; Lambert JM; Counter CM; Der CJ; Cox AD
Methods Enzymol; 2006; 407():556-74. PubMed ID: 16757353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
